- Home
- LNKB vs GLSI Comparison
LNKB vs GLSI Comparison
Compare LNKB & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNKB | GLSI |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.5M | 327.2M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LNKB | GLSI |
|---|---|---|
| Price | $8.68 | $26.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 423.6K | 104.2K |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | ★ 26.76 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $186,504,000.00 | N/A |
| Revenue This Year | $10.18 | N/A |
| Revenue Next Year | $9.33 | N/A |
| P/E Ratio | $9.66 | ★ N/A |
| Revenue Growth | ★ 11.29 | N/A |
| 52 Week Low | $6.57 | $7.78 |
| 52 Week High | $9.59 | $34.10 |
Technical Indicators
Market Signals| Indicator | LNKB | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 52.04 |
| Support Level | $8.44 | $21.21 |
| Resistance Level | $9.03 | $29.89 |
| Average True Range (ATR) | 0.17 | 2.02 |
| MACD | -0.02 | 0.24 |
| Stochastic Oscillator | 38.26 | 49.92 |
Price Performance
Historical ComparisonAbout LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.